{"title":"别嘌醇治疗小儿多发性硬化症","authors":"Yousef A Assaleh , Farah Thabet , Kalthoum Graies-Tlili , Brahim Tabarki","doi":"10.1016/j.nerep.2024.100209","DOIUrl":null,"url":null,"abstract":"<div><p>We report a 12-year-old male patient with relapsing-remitting multiple sclerosis who showed a strong response to allopurinol with no safety concern. Researchers should further evaluate this drug option in multiple sclerosis.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"5 ","pages":"Article 100209"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X2400010X/pdfft?md5=639bd7ffb8f177130b1c9dca42216400&pid=1-s2.0-S2667257X2400010X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Allopurinol treatment in pediatric multiple sclerosis\",\"authors\":\"Yousef A Assaleh , Farah Thabet , Kalthoum Graies-Tlili , Brahim Tabarki\",\"doi\":\"10.1016/j.nerep.2024.100209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We report a 12-year-old male patient with relapsing-remitting multiple sclerosis who showed a strong response to allopurinol with no safety concern. Researchers should further evaluate this drug option in multiple sclerosis.</p></div>\",\"PeriodicalId\":100950,\"journal\":{\"name\":\"Neuroimmunology Reports\",\"volume\":\"5 \",\"pages\":\"Article 100209\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2667257X2400010X/pdfft?md5=639bd7ffb8f177130b1c9dca42216400&pid=1-s2.0-S2667257X2400010X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimmunology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667257X2400010X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X2400010X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Allopurinol treatment in pediatric multiple sclerosis
We report a 12-year-old male patient with relapsing-remitting multiple sclerosis who showed a strong response to allopurinol with no safety concern. Researchers should further evaluate this drug option in multiple sclerosis.